Here is the latest shareholding Pattern of J.B.CHEMICALS. For more details, see the J.B.CHEMICALS financial fact sheet and J.B.CHEMICALS share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Jun-20 |
3
Sep-20 |
3
Dec-20 |
3
Mar-21 |
3
Jun-21 |
3
Sep-21 |
3
Dec-21 |
3
Mar-22 |
||
---|---|---|---|---|---|---|---|---|---|---|
Indian Promoters | % | 55.91 | 45.91 | 1.91 | 1.91 | 1.91 | 1.91 | 0.00 | 0.00 | |
Foreign Promoters | % | 0.00 | 10.00 | 54.00 | 54.00 | 54.00 | 54.00 | 54.00 | 54.00 | |
Total Promoters | % | 55.91 | 55.91 | 55.91 | 55.91 | 55.91 | 55.91 | 54.00 | 54.00 | |
Mutual Funds | % | 12.23 | 10.60 | 12.06 | 10.56 | 10.55 | 12.80 | 13.75 | 14.27 | |
Financial institution/Banks/Insurance | % | 0.95 | 1.04 | 1.17 | 1.84 | 1.77 | 1.96 | 2.28 | 2.39 | |
Government | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
FII | % | 7.78 | 7.25 | 7.87 | 7.54 | 8.37 | 8.74 | 9.12 | 9.22 | |
Other | % | 1.17 | 0.74 | 0.68 | 0.77 | 0.81 | 0.47 | 0.23 | 0.23 | |
Total Institution | % | 22.13 | 19.63 | 21.78 | 20.71 | 21.50 | 23.97 | 25.38 | 26.11 | |
Bodies Corporate | % | 1.08 | 1.83 | 0.96 | 1.18 | 1.16 | 0.88 | 0.75 | 0.70 | |
Individuals | % | 19.05 | 20.73 | 19.70 | 20.49 | 19.68 | 17.64 | 18.38 | 17.86 | |
NRIs/OCBs | % | 1.32 | 1.33 | 1.30 | 1.33 | 1.34 | 1.19 | 1.04 | 0.99 | |
ADR/GDR | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Others | % | 0.51 | 0.58 | 0.35 | 0.38 | 0.40 | 0.41 | 0.45 | 0.34 | |
Total Non-Institution | % | 21.96 | 24.47 | 22.31 | 23.38 | 22.58 | 20.12 | 20.62 | 19.89 | |
Total Public | % | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 46.00 | 46.00 | |
Grand Total | % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
Pledged Promoter Holding | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
![]() |
More Pharmaceuticals Company Shareholding Pattern: ZYDUS LIFESCIENCES DR. REDDYS LAB CIPLA LUPIN SUN PHARMA
Asian share markets erased early gains and fell in the negative territory tracking a sharp fall on Wall Street.
The company seeks to expand the market for prescription lozenges with new launches this year.
It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.
Here's why Divi's Lab's stock fell over 10% in two days.
For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
More Views on NewsWith India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.
Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.
This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.
The #1 make or break factor in your portfolio you shouldn't ignore.
In this video I'll show you why I think the market correction could be coming to an end.
More